期刊文献+

国产多烯紫杉醇及联合顺铂治疗非小细胞肺癌临床研究 被引量:4

Clinical research of treatment of non-small-cell lung cancer (NSCLC) resulted from docetaxel-based chemotherapy
下载PDF
导出
摘要 目的探讨国产多西紫杉醇(多帕菲,齐鲁制药)单用以及多帕菲+顺铂联合化疗方案对非小细胞肺的临床疗效和安全性,并以进口多西紫杉醇(泰索帝)+顺铂联合化疗方案作对照。方法患者随机分入多帕菲单用组(A组,41例):多帕菲40mg/m2i.v.qw×6,每8周为1周期;多帕菲+顺铂组(B组,40例):多帕菲75mg/m2i.v.d1+顺铂80mg/m2i.v.分3d用,每21d为1周期;泰索帝+顺铂组(C组,43例):泰索帝75mg/m2i.v.d1+顺铂80mg/m2i.v.分3d用,每21d为1周期。结果入组的124例中116例可评价疗效,A、B和C组有效率分别为17.95%、21.62%、25.00%。B和C组有效率相似。不良反应主要有中性粒细胞减少、贫血、粒细胞减少性发热、其他发热、脱发、恶心呕吐和乏力。C组中性粒细胞减少的发生率高于B组,两组间差异有显著性(P<0.05)。其余不良反应两组相似。结论国产多西紫杉醇(多帕菲)+顺铂与进口多西紫杉醇(泰索帝)+顺铂两联合化疗方案相似,对非小细胞肺癌有一定疗效,且毒性可耐受。 [Objective] To investigate prospectively the efficacy and safety of docetaxel and two docetaxel plus cisplatin regimens in patients suffered from non-small-cell lung cancer(NSCLC). [Methods] 124 patients suffered from NSCLC between January 2004 and March 2005 were randomly assigned to receive a docetaxel-based chemotherapy, i.e. single-agent docetaxel (Zhusheyong Duoxitasai) 40 mg/m^2 i.v. qwx6 every 8 weeks(A group, 41 cases); docetaxel (Zhusheyong Duoxitasai) 75 mg/m^2 i.v.dl plus cisplatin 80rag/m^2 i.v. every 3 weeks(B group, 40 cases); docetaxel (Taxotere) 75mg/m^2 i.v.dl plus cisplatin 80 mg/m^2 i.v. every 3 weeks (C group 43 ). [Results] 116 of 124 patients were evaluable for efficacy. Overall response rates of A, B and C were 17.95%, 21.62% and 25.00%, respectively. Response within B group was similar to within C group. The major toxicities were neutropenia, anemia, febrile neutropenia, fever, alopecia, nausea, vomiting and fatigue. Neutropenia was more common within C group than within B group (P 〈0.05). [Conclusion] Two docetaxel plus cisplatin regimens are effective and well-tolerated treatment in patients suffered from NSCLC.
出处 《中国医学工程》 2005年第6期622-625,共4页 China Medical Engineering
关键词 非小细胞肺癌 多西紫杉醇 顺铂 治疗 Non-small-cell lung cancer(NSCLC) docetaxel cisplatin treatment
  • 相关文献

参考文献7

二级参考文献36

  • 1[1]Rizvi NA. Docetaxel (taxotere) and gemcitabine in combination therapy. Semin Oncol,1999,26(3 Suppl 11)∶19-22. 被引量:1
  • 2[2]van Oosterom AT. Docetaxel (taxotere) and gemcitabine phase Ⅰand early phase Ⅱ studies: results to date and an overview of ongoing studies. Semin Oncol,1999,26(3 Suppl 10)∶8-11. 被引量:1
  • 3[3]Rizvi NA, Spiridonidis CH, Davis TH, et al. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin Oncol,1999,26(5 Suppl 16)∶27-31. 被引量:1
  • 4[5]Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (taxotere): summary of clinical data. Semin Oncol,1999,26(3 Suppl 10)∶19-24. 被引量:1
  • 5[6]Chu DT. Phase Ⅰ trial of weekly docetaxel (D) plus cisplatin (C) in the treatment of advanced NSCLC in Chinese patients. Proc Am Soc Clin Oncol,2002,21∶2744. 被引量:1
  • 6[7]Spiridonidis CH, Laufman LR, Jones J, et al. Phase Ⅰ study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol,1998,16(12)∶3866-3873. 被引量:1
  • 7[1]Non-small-cell Lung Cancer Collaborative Group:Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials[ J ]. BMJ,1995,311 (7010) :899-909. 被引量:1
  • 8[2]Comer AL, Goa KL. Docetaxel:a review of its use in non-smallcell lung cancer[ J ]. Drug & Aging,2000,17 ( 1 ) :53-80. 被引量:1
  • 9[3]Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1052 patients. [ J ]. J CLin Oncol,1995,13(5 ): 1221-1230. 被引量:1
  • 10[4]Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [ J ]. J Clin Oncol , 2000,18 ( 10 ):2095-2103. 被引量:1

共引文献22

同被引文献48

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部